Taiwan Liposome Co (TLC, 台灣微脂體) is seeking streamlined US regulatory approval for its efforts in treating pediatric rhabdomyosarcoma, a rare disorder affecting about 350 children in Taiwan.
TLC, which developed a proprietary lipid-assembled delivery platform for nanomedicine injections, is looking to qualify for the US Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher program that provides incentives for sponsors that receive approval for biologics license applications.
The company’s technology traps the active pharmaceutical ingredient in multiple layers of lipids to promote fast-acting and sustained release of active pharmaceutical ingredients, as well as reducing the frequency of required injections.
The company’s treatments can also be administered with smaller-gauge needles, which provides broader use for physicians.
The voucher grants priority review of a subsequent marketing application for a different product and the treatment can be sold for more than US$100 million to other drug developers vying to beat rivals to the market, TLC president George Yeh (葉志鴻) said at an earnings conference in Taipei.
To earn the voucher, the company would start clinical trials for TLC178, its target-delivered nanomedicine for managing tumor growth, before the end of the first half of the year, Yeh said, adding that studies for rare diseases are single-armed.
In addition to TLC178, three other products are expected to enter the trial stage before the end of next year, Yeh said, adding that the firm’s lipid-based technology has produced favorable results in clinical trials.
TLC599, a sustained release therapy for the treatment of osteoarthritis pain, has shown minimal cartilage damage among patients while providing fast-acting as well as sustained pain relief, Yeh said.
TLC590, which brings sustained release delivery technology to the common local anesthetic ropivacaine, is designed as an alternative post-surgery pain management therapy to combat rising opioid addiction, he said.
Similarly, TLC399 provides sustained release for macular edema without the need to insert an implant in the eye, he added.
Overall, the US FDA has been very positive about alternatives for opioids in previous meetings with the company, Yeh said.
TLC’s pain management products are expected to be highly competitive in the US market as they can be produced in low-cost manufacturing environments, he said.
Regarding the company’s plans to list American depositary receipts (ADRs) on the NASDAQ, Yeh said that the move would help raise the company’s profile in the US, its biggest target market.
The issue price is expected to be more than NT$72 per ADR, the same level the company’s shares were trading at the time of application in November last year.
The company decided on an overseas listing because it is tougher to gain a higher valuation in Taiwan with its investment requirements, he added.
The company, which is still seeking market approval for its new drugs, posted net losses of NT$873 million (US$29.79 million) for last year.
Shares of TLC yesterday dipped 6.61 percent to NT$100.5 in Taipei trading.
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Intel Corp has received licenses from US authorities to continue supplying certain products to Huawei Technologies Co (華為), a company spokesman said yesterday. Washington has been pushing governments around to world to squeeze out Huawei, saying that the telecom giant would hand data to Beijing for espionage. From Monday last week, new curbs have barred US companies from supplying or servicing Huawei. This week, the state-backed China Securities Journal reported that Intel had received permission to supply Huawei. China’s Semiconductor Manufacturing International Corp (SMIC, 中芯國際), which uses US-origin equipment to make chips for Huawei and other companies, last week confirmed that it had sought
INVEST IN TAIWAN: A metal components casting firm and the world’s largest maker of aluminum bicycle rims also obtained approvals to join the program Solar Applied Materials Technology Co (SOLAR, 光洋應用材料), a part of Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) “green supply chain,” has pledged to invest NT$1 billion (US$34.1 million) to build a new plant at the Tainan Technology Industrial Park (台南科技工業區), the Ministry of Economic Affairs said yesterday. SOLAR has been collaborating with TSMC to extract precious metals from waste and reuse them as “sputtering target” material in high-end semiconductor manufacturing, a TSMC press release issued in May said. Established in 1978, SOLAR also offers key materials and integrated services to customers in the optoelectronics, information and communications technology, petrochemicals and consumer electronics industries,
Swancor Renewable Energy Co (上緯新能源) yesterday announced plans for a 4.4 gigawatt (GW) offshore wind project off Miaoli County as part of its commitment toward Taiwan’s energy transformation, the company said in a statement. The “Formosa 4” project includes three deep-water wind farms 18km to 20km off the coast, Swancor Renewable CEO Lucas Lin (林雍堯) said, adding that planning for the project began last year. A proposal for Formosa 4 was this week submitted to the Environmental Protection Agency (EPA), the company said. Swancor Renewable jointly developed the Formosa 1 project, a 128 megawatt (MW) wind farm about 4km off Miaoli and the